Circulating stem cell–like epithelial cell adhesion molecule–positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection

Epithelial cell adhesion molecule–positive (EpCAM+) hepatocellular carcinoma (HCC) cells may constitute a tumor‐initiating subpopulation in tumorigenic cell lines and HCC specimens. In the present study, EpCAM+ circulating tumor cells (CTCs) were identified prospectively in HCC patients undergoing curative resection, and the prognostic significance and their stem cell–like characteristics were investigated further. Blood samples from 123 HCC patients were tested prior to resection and 1 month thereafter. CTCs were present in 66.67% of patients, and the cell count measured in 7.5 mL of blood (CTC7.5) ranged between 1 and 34. Fifty‐one patients had CTC7.5 of ≥2 preoperatively, and these patients developed tumor recurrence earlier than those with CTC7.5 of <2 CTCs (P < 0.001). A preoperative CTC7.5 of ≥2 was an independent prognostic factor for tumor recurrence (P < 0.001). Its prognostic significance also applied to patients with alpha‐fetoprotein (AFP) levels of ≤400 ng/mL or subgroups with low recurrence risk (all P < 0.05). A significant decrease of CTC‐positive rates (66.67% to 28.15%, P < 0.05) and CTC7.5 values (2.60 ± 0.43 to 1.00 ± 0.36, P < 0.05) was observed 1 month after resection. Patients with consistent CTC7.5 <2 had lower recurrence rates than those with values consistently ≥2 (15.5% versus 87.50%, P < 0.001). EpCAM+ CTCs displayed cancer stem cell biomarkers (CD133 and ABCG2), epithelial‐mesenchymal transition, Wnt pathway activation, high tumorigenic potential, and low apoptotic propensity. Conclusion: Stem cell–like phenotypes are observed in EpCAM+ CTCs, and a preoperative CTC7.5 of ≥2 is a novel predictor for tumor recurrence in HCC patients after surgery, especially in patient subgroups with AFP levels of ≤400 ng/mL or low tumor recurrence risk. EpCAM+ CTCs may serve as a real‐time parameter for monitoring treatment response and a therapeutic target in HCC recurrence. (HEPATOLOGY 2013)

[1]  E. Perez,et al.  Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437 , 2011, Clinical Cancer Research.

[2]  Jia Fan,et al.  Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance , 2011, Journal of Cancer Research and Clinical Oncology.

[3]  Hans Clevers,et al.  The cancer stem cell: premises, promises and challenges , 2011, Nature Medicine.

[4]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[5]  Giuseppe Naso,et al.  Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients , 2011, Breast Cancer Research and Treatment.

[6]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[7]  Michael Kahn,et al.  Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells? , 2010, Clinical Cancer Research.

[8]  S. Qiu,et al.  High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma , 2010, Gut.

[9]  Larry Norton,et al.  Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.

[10]  Harris Markomanolaki,et al.  Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients , 2009, Breast Cancer Research.

[11]  Anne-Michelle Noone,et al.  Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Qiu,et al.  CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery , 2009, Clinical Cancer Research.

[13]  Tanja Fehm,et al.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.

[14]  S. Iyer,et al.  Perioperative Factors Affecting Long-Term Outcomes of 473 Consecutive Patients Undergoing Hepatectomy for Hepatocellular Carcinoma , 2009, Annals of Surgical Oncology.

[15]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[16]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[17]  T. Mok,et al.  New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Zhi-quan Wu,et al.  Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection , 2008, Clinical Cancer Research.

[20]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[21]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[22]  Steven Gallinger,et al.  Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. , 2007, Surgery.

[23]  C. Wittekind,et al.  Pitfalls in der Klassifikation von Lebertumoren , 2006, Der Pathologe.

[24]  S. Gallinger,et al.  Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. , 2006, Journal of the American College of Surgeons.

[25]  K. Pienta,et al.  Apoptosis of circulating tumor cells in prostate cancer patients , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[26]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[27]  Q. Ye,et al.  Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. , 2004, World journal of gastroenterology.

[28]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[29]  W. Jarnagin,et al.  Predictors and patterns of recurrence after resection of hepatocellular carcinoma. , 2003, Journal of the American College of Surgeons.

[30]  S. Fan,et al.  Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Kubista,et al.  Circulating breast cancer cells are frequently apoptotic. , 2001, The American journal of pathology.

[32]  S. Fan,et al.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. , 2000, Annals of surgery.

[33]  최기홍,et al.  Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis , 2011 .

[34]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[35]  C. Wittekind.  [Pitfalls in the classification of liver tumors]. , 2006, Der Pathologe.

[36]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.